Expression analysis of δ-catenin and prostate-specific membrane antigen:: Their potential as diagnostic markers for prostate cancer
Expression analysis of δ-catenin and prostate-specific membrane antigen:: Their potential as diagnostic markers for prostate cancer
复制标题
DOI：
10.1002/ijc.10468
复制
发表时间：
2002-07-10
影响因子：
6.4
通讯作者：
Gardiner, RA
中科院分区：
文献类型：
--
作者：
Burger, MJ;Tebay, MA;Gardiner, RA
目前的前列腺癌诊断方法具有主要局限性，包括前列腺特异性抗原（PSA）测定无法准确区分前列腺癌和良性前列腺增生（BPH）以及经直肠超声（TRUS）活检取样的不精确性。我们采用cDNA微阵列筛选比较BPH和肿瘤样本中的基因表达模式，以确定可能有助于区分这些条件的表达标志物。筛选3个单独的cDNA阵列确定了8个基因的表达3倍以上，在6个肿瘤组织比1个非肿瘤样品和I BPH样品。使用实时PCR来确认这8个基因和从文献中选择的12个基因针对一组17个肿瘤和11个BPH样品的过表达。与BPH相比，两种基因，δ-连环蛋白（δ-catenin; CTNND 2）和前列腺特异性膜抗原（PSMA; FOLH 1）在前列腺癌中显著过表达。在我们的前列腺癌组织中，前列腺上皮细胞对S-连环蛋白和PSMA染色阳性，而我们的大多数BPH组织对这两种标记物均呈阴性。因此，我们已经确定了δ-连环蛋白（以前与前列腺腺癌无关），并证实了PSMA作为前列腺癌诊断和治疗的潜在候选者的潜力。(C)2002年威利-利斯。Inc.
The current approach to prostate cancer diagnosis has major limitations including the inability of prostate-specific antigen (PSA) assays to accurately differentiate between prostate cancer and benign prostate hyperplasia (BPH) and the imprecision of transrectal ultrasound (TRUS) biopsy sampling. We have employed cDNA microarray screening to compare gene expression patterns in BPH and tumour samples to identify expression markers that may be useful in discriminating between these conditions. Screening of 3 individual cDNA arrays identified 8 genes with expression 3-fold greater in 6 tumour tissues than in 1 nontumour sample and I BPH sample. Real-time PCR was used to confirm the overexpression of these 8 genes and 12 genes selected from the literature against a panel of 17 tumours and I 1 BPH samples. Two genes, delta-catenin (delta-catenin; CTNND2) and prostate-specific membrane antigen (PSMA; FOLH1), were significantly overexpressed in prostate cancer compared to BPH. Prostate epithelial cells stained positively for S-catenin and PSMA in our prostate cancer tissues, whereas the majority of our BPH tissues were negative for both markers. Thus we have identified delta-catenin (not previously associated with prostatic adenocarcinoma) and confirmed the potential of PSMA as potential candidates for the diagnosis and management of prostate cancer. (C) 2002 Wiley-Liss. Inc.